Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights
BRACELET-1 data showing impressive overall survival benefit in HR+/HER2- metastatic breast cancer affirms pelareorep + paclitaxel combination should be evaluated in a registrational study
Upcoming GOBLET milestones include updated efficacy data from anal cancer cohort and safety run-in data from the modified FOLFIRINOX pancreatic cancer cohort
Cash position of $19.6 million as of
Management hosting conference call and webcast today at 8:30 a.m. ET
Third Quarter Highlights
BRACELET-1 data exceeds expectations, providing clear evidence of pelareorep's ability to improve outcomes in patients with advanced HR+/HER2- breast cancer (link to press release), demonstrating progression-free survival of 12.1 months for pelareorep + paclitaxel compared to 6.4 months for paclitaxel alone, yielding a benefit of 5.7 months. Additionally, 64% of patients treated with pelareorep + paclitaxel lived at least two years compared to only 33% of patients treated with paclitaxel alone. Overall survival could not be calculated as more than half of the pelareorep + paclitaxel patients were alive at the end of the study. Assuming the remaining patients survived only until their next planned follow-up visit, the median overall survival would have been 32.1 months, which compares favorably to the 18.2 months recorded for patients who received paclitaxel monotherapy.
Financial Highlights
- As of
September 30, 2024 , the Company reported$19.6 million in cash and cash equivalents. The Company has a projected cash runway through key milestones and into 2025. - The net loss for the third quarter of 2024 was
$9.5 million , compared to a net loss of$9.9 million for the third quarter of 2023. The basic and diluted loss per share was$0.12 in the third quarter of 2024, compared to a basic and diluted loss per share of$0.14 in the third quarter of 2023. - Research and development expenses for the third quarter of 2024 were
$6.8 million , compared to$5.8 million for the third quarter of 2023. The increase was primarily due to higher manufacturing expenses and clinical trial expenses. - General and administrative expenses for the third quarter of 2024 were
$3.1 million , compared with$5.2 million for the third quarter of 2023. The decrease was primarily due to lower investor relations activities and transaction costs as part of our public offering in 2023. - Net cash used in operating activities for the nine months ended
September 30, 2024 was$19.1 million , compared to$22.3 million for the nine months endedSeptember 30, 2023 . The decrease reflected non-cash working capital changes, partly offset by higher net operating activities in 2024.
Recent and Anticipated Milestones
- H1 2025: Finalize master protocol for the adaptive registration-enabling trial for pelareorep, gemcitabine, nab-paclitaxel, and atezolizumab in first-line pancreatic ductal adenocarcinoma (PDAC) with the
Global Coalition for Adaptive Research (GCAR) and submit it to the FDA - H1 2025: Safety run-in data from cohort 5 of the GOBLET study, investigating pelareorep and modified FOLFIRNOX (mFOLFIRINOX) with or without atezolizumab in newly diagnosed pancreatic cancer
- H1 2025: updated efficacy data from cohort 4 of the GOBLET study, investigating pelareorep and atezolizumab in second-line or later anal cancer
- Mid 2025: First patient enrolled in registration-enabling study evaluating pelareorep and paclitaxel in metastatic HR+/HER2- breast cancer
- H2 2025: Initial efficacy results from cohort 5 of the GOBLET study, investigating pelareorep and mFOLFIRINOX with or without atezolizumab in newly diagnosed pancreatic cancer
Webcast and Conference Call
Management will host a conference call for analysts and investors at
|
|
|||
|
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION |
|||
|
(unaudited) |
|||
|
(in thousands of Canadian dollars, except share amounts) |
|||
|
As at |
|
|
|
|
Assets |
|
|
|
|
Current assets |
|
|
|
|
Cash and cash equivalents |
$ 19,598 |
|
$ 34,912 |
|
Other receivables |
104 |
|
15 |
|
Prepaid expenses |
2,119 |
|
3,246 |
|
Warrant derivative |
1,092 |
|
— |
|
Total current assets |
22,913 |
|
38,173 |
|
Property and equipment |
422 |
|
282 |
|
Right-of-use assets |
927 |
|
365 |
|
Total assets |
$ 24,262 |
|
$ 38,820 |
|
Liabilities and Shareholders' Equity |
|
|
|
|
Current liabilities |
|
|
|
|
Accounts payable and accrued liabilities |
$ 6,922 |
|
$ 3,572 |
|
Other liabilities |
489 |
|
332 |
|
Lease liabilities |
251 |
|
133 |
|
Warrant derivative |
— |
|
200 |
|
Total current liabilities |
7,662 |
|
4,237 |
|
Contract liability |
6,730 |
|
6,730 |
|
Lease liabilities |
813 |
|
290 |
|
Total liabilities |
15,205 |
|
11,257 |
|
Commitments |
|
|
|
|
Shareholders' equity |
|
|
|
|
Share capital Authorized: unlimited
Issued:
|
434,460 |
|
430,906 |
|
Contributed surplus |
43,640 |
|
42,116 |
|
Accumulated other comprehensive income |
653 |
|
544 |
|
Accumulated deficit |
(469,696) |
|
(446,003) |
|
Total shareholders' equity |
9,057 |
|
27,563 |
|
Total liabilities and shareholders' equity |
$ 24,262 |
|
$ 38,820 |
|
|
|||||||
|
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS |
|||||||
|
(unaudited) |
|||||||
|
(in thousands of Canadian dollars, except share amounts) |
|||||||
|
|
Three Months Ended |
|
Nine Months Ended |
||||
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
|
Expenses |
|
|
|
|
|
|
|
|
Research and development |
$ 6,794 |
|
$ 5,811 |
|
$ 17,095 |
|
$ 13,051 |
|
General and administrative |
3,105 |
|
5,237 |
|
9,450 |
|
11,891 |
|
Loss before the following |
(9,899) |
|
(11,048) |
|
(26,545) |
|
(24,942) |
|
Change in fair value of warrant derivative |
229 |
|
515 |
|
1,333 |
|
439 |
|
Foreign exchange (loss) gain |
(122) |
|
310 |
|
579 |
|
(83) |
|
Interest income, net |
261 |
|
305 |
|
1,047 |
|
837 |
|
Loss before income taxes |
(9,531) |
|
(9,918) |
|
(23,586) |
|
(23,749) |
|
Income tax expense |
(12) |
|
(7) |
|
(107) |
|
(54) |
|
Net loss |
(9,543) |
|
(9,925) |
|
(23,693) |
|
(23,803) |
|
Other comprehensive (loss) income items that may be |
|
|
|
|
|
|
|
|
Translation adjustment |
(69) |
|
101 |
|
109 |
|
(7) |
|
Net comprehensive loss |
$ (9,612) |
|
$ (9,824) |
|
$ (23,584) |
|
$ (23,810) |
|
|
|
|
|
|
|
|
|
|
Basic and diluted loss per common share |
$ (0.12) |
|
$ (0.14) |
|
$ (0.31) |
|
$ (0.36) |
|
Weighted average number of shares (basic and |
77,016,848 |
|
69,803,255 |
|
76,120,580 |
|
65,565,890 |
|
|
|||||||||
|
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY |
|||||||||
|
(unaudited) |
|||||||||
|
(in thousands of Canadian dollars) |
|||||||||
|
|
Share Capital |
|
Contributed |
|
Accumulated |
|
Accumulated |
|
Total |
|
As at |
$ 404,040 |
|
$ 40,051 |
|
$ 662 |
|
$ (418,251) |
|
$ 26,502 |
|
Net loss and other comprehensive loss |
— |
|
— |
|
(7) |
|
(23,803) |
|
(23,810) |
|
Issued pursuant to stock option plan |
662 |
|
(256) |
|
— |
|
— |
|
406 |
|
Issued pursuant to "At the Market" Agreement |
9,128 |
|
— |
|
— |
|
— |
|
9,128 |
|
Issued pursuant to public offering |
17,724 |
|
638 |
|
— |
|
— |
|
18,362 |
|
Share issue costs |
(2,728) |
|
— |
|
— |
|
— |
|
(2,728) |
|
Share-based compensation expense |
— |
|
1,158 |
|
— |
|
— |
|
1,158 |
|
As at |
$ 428,826 |
|
$ 41,591 |
|
$ 655 |
|
$ (442,054) |
|
$ 29,018 |
|
|
|
|
|
|
|
|
|
|
|
|
As at |
$ 430,906 |
|
$ 42,116 |
|
$ 544 |
|
$ (446,003) |
|
$ 27,563 |
|
Net loss and other comprehensive income |
— |
|
— |
|
109 |
|
(23,693) |
|
(23,584) |
|
Issued pursuant to incentive share award plan |
3 |
|
(3) |
|
— |
|
— |
|
— |
|
Issued pursuant to "At the Market" Agreement |
4,062 |
|
— |
|
— |
|
— |
|
4,062 |
|
Issued pursuant to warrant derivative exercised |
71 |
|
— |
|
— |
|
— |
|
71 |
|
Share issue costs |
(582) |
|
— |
|
— |
|
— |
|
(582) |
|
Share-based compensation expense |
— |
|
1,527 |
|
— |
|
— |
|
1,527 |
|
As at |
$ 434,460 |
|
$ 43,640 |
|
$ 653 |
|
$ (469,696) |
|
$ 9,057 |
|
|
||||
|
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS |
||||
|
(unaudited) |
||||
|
(in thousands of Canadian dollars) |
||||
|
|
|
Nine Months Ended |
||
|
|
|
2024 |
|
2023 |
|
Operating Activities |
|
|
|
|
|
Net loss for the period |
|
$ (23,693) |
|
$ (23,803) |
|
Depreciation - property and equipment |
|
92 |
|
62 |
|
Depreciation - right-of-use-assets |
|
234 |
|
234 |
|
Share-based compensation expense |
|
1,527 |
|
1,158 |
|
Compensation warrant expenses |
|
— |
|
151 |
|
Interest expense on lease liabilities |
|
99 |
|
53 |
|
Unrealized foreign exchange (gain) loss |
|
(544) |
|
21 |
|
Change in fair value of warrant derivative |
|
(1,333) |
|
(439) |
|
Net change in non-cash working capital |
|
4,498 |
|
239 |
|
Cash used in operating activities |
|
(19,120) |
|
(22,324) |
|
Investing Activities |
|
|
|
|
|
Acquisition of property and equipment |
|
(233) |
|
(5) |
|
Maturities of marketable securities |
|
— |
|
20,230 |
|
Cash (used in) provided by investing activities |
|
(233) |
|
20,225 |
|
Financing Activities |
|
|
|
|
|
Proceeds from exercise of stock options |
|
— |
|
406 |
|
Proceeds from exercise of warrant derivative |
|
65 |
|
— |
|
Proceeds from "At the Market" equity distribution agreement, net |
|
3,480 |
|
8,790 |
|
Proceeds from public offering |
|
— |
|
21,359 |
|
Payment of lease liabilities |
|
(248) |
|
(303) |
|
Cash provided by financing activities |
|
3,297 |
|
30,252 |
|
(Decrease) increase in cash and cash equivalents |
|
(16,056) |
|
28,153 |
|
Cash and cash equivalents, beginning of period |
|
34,912 |
|
11,666 |
|
Impact of foreign exchange on cash and cash equivalents |
|
742 |
|
162 |
|
Cash and cash equivalents, end of period |
|
$ 19,598 |
|
$ 39,981 |
About
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For further information, please visit: www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @oncolytics.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential, mechanism of action and benefits of pelareorep as a cancer therapeutic, including pelareorep's potential in HR+/HER2- metastatic breast cancer and the estimated overall survival benefit of pelareorep-based therapy; our belief that pelareorep is poised to advance to a registration-enabling study; continued development of our gastrointestinal cancer program; our expectations regarding the presentation of efficacy and safety data from anal and pancreatic cancer cohorts
;
the potential market and commercial opportunities for pelareorep; our confidence in pelareorep's potential to meaningfully improve patient outcomes; Oncolytics' projected cash runway; our plan to conduct a registration-enabling study to assess pelareorep-based combination therapy in patients with advanced HR+/HER2- breast cancer and the anticipated timing thereof; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and
|
Company Contact
Director of IR & Communication |
Investor Relations for Oncolytics
+1-917-679-9282 |
Logo: https://mma.prnewswire.com/media/2408622/Oncolytics_Biotech_Inc_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/oncolytics-biotech-reports-third-quarter-2024-financial-results-and-operational-highlights-302302455.html
SOURCE Oncolytics Biotech® Inc.
